Stoke Therapeutics (NASDAQ:STOK) is preparing to release its quarterly earnings on Tuesday, 2025-08-12. Here’s a brief overview of what investors should keep in mind before the announcement.
Analysts expect Stoke Therapeutics to report an earnings per share (EPS) of $-0.55.
Investors in Stoke Therapeutics are eagerly awaiting the company’s announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It’s worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
Earnings Track Record
Last quarter the company beat EPS by $2.51, which was followed by a 0.67% increase in the share price the next day.
Here’s a look at Stoke Therapeutics’s past performance and the resulting price change:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.61 | -0.54 | -0.53 | -0.55 |
| EPS Actual | 1.90 | -0.18 | -0.47 | -0.46 |
| Price Change % | 1.0% | -7.000000000000001% | 2.0% | 3.0% |
Performance of Stoke Therapeutics Shares
Shares of Stoke Therapeutics were trading at $13.1 as of August 08. Over the last 52-week period, shares are down 6.05%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.
Analyst Views on Stoke Therapeutics
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Stoke Therapeutics.
Analysts have given Stoke Therapeutics a total of 3 ratings, with the consensus rating being Buy. The average one-year price target is $29.0, indicating a potential …